

14 October 2025

Coagulation Factors in Treating Haemophilia A and B and von Willebrand Patients

In the last 3 months (July, August, September 2025), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your Trust and how much volume (IUs or mg) was used?

	Number of treated patients	Volume used (IUs, mg)
Hemlibra (non-inhibitor patients)		
Hemgenix		
Altuvoct		
Advate		
Adynovi		
Elocta		
Esperoct		
NovoEight		
ReFacto AF		
Nuwiq		
Hympavzi		
Idelvion		
Refixia		
Alprolix		
BeneFIX		
Replenine		
Rixubis		
Veyvondi		
Voncento		
Wilate		
Willfact		

The information requested above, is exempt under Section 21 - Information accessible to applicant by other means.

The information requested is readily available from the National Haemophilia Database (NHD).



FOI/35113

14 October 2025

Belfast Health and Social Care Trust supplies treatment in line with the National Framework and reports all diagnosis, treatments and regimes, on a quarterly basis, to the National Haemophilia Database provided by the UKHCDO.

Any individual / company can apply to the National Haemophilia Database for this information.

NHD – UKHCDO

Contact: publicliaison@belfasttrust.hscni.net